No abstract

Aim: To evaluate the aspartate aminotransferase platelet ratio index (APRI) score in the prediction of intrahepatic cholestasis (ICP) in the second-third trimester of pregnancy. Material and Methods: The patient group (n=40) and control group (n=70) diagnosed with ICP who applied to the hospital Perinatology clinic between 2021-2022 were included in this study. Laboratory tests of both groups were analyzed retrospectively. Age, gravida, parity, body mass index, third trimester laboratory tests and first trimester aspartate aminotransferase (AST)/platelet count ratio [AST - platelet ratio index (APRI) score] APRI scores were compared between the two groups. The relationship between APRI score index and neonatal outcomes was evaluated in the study group.In the study, the cut-off value of the APRI score was determined for predicting ICP in second-third trimester in pregnant women. Results: Patients with ICP had significantly higher APRI scores compared with controls (p

ObjectiveTo evaluate the aspartate aminotransferase to platelet ratio (APRI) score as a predictive and prognostic test in intrahepatic cholestasis of pregnancy (ICP).MethodsThis study was conducted in 198 patients diagnosed with ICP and 204 healthy pregnant women who presented to a tertiary center between 2019 and 2022. APRI scores; laboratory findings in the first, second, and third trimesters; and perinatal outcomes were compared between the two groups. The ICP group was evaluated for correlation between APRI scores and composite adverse outcomes. Two different receiver operating characteristic analyses were performed to determine optimal cutoff values of predictive APRI score of ICP and composite adverse outcomes in patients with ICP.ResultsAspartate aminotransferase values and APRI scores were significantly higher in the ICP group in all trimesters (P < 0.001). The optimal cutoff values of APRI scores to predict ICP for the first, second, and third trimesters were 0.101 (79.7% sensitivity, 79.6% specificity), 0.103 (78.4% sensitivity, 76.3% specificity), and 0.098 (72.5% sensitivity, 72% specificity), respectively. APRI scores were statistically higher in patients with ICP with composite adverse outcomes in all trimesters (P values of 0.03, 0.04, and 0.01, respectively).ConclusionAPRI score was found to be a valuable predictor of ICP and its adverse outcomes during the entire pregnancy.